Shares of Eli Lilly surged +4.4% to $1,344.79 after the company reported that its experimental injectable, retatrutide, demolished Novo Nordisk's Ozempic in the first direct Phase 3 comparison between the two drugs. Patients on retatrutide lost roughly twice as much weight over 80 weeks — 19.5% to 20.9% of body weight versus just 9.4% on Ozempic — while also reducing blood sugar (A1C) by 2.2 percentage points compared to 1.8 on Ozempic. The rally lands on a week when Lilly also reported blowout Q3 earnings, creating a rare one-two punch for bulls.

  • Twice the Weight Loss Gives Lilly Its Sharpest Weapon Against Novo Nordisk. Retatrutide mimics three gut hormones — GLP-1, GIP, and glucagon — one more than any approved competitor , and the data proved that advantage translates to real patients. Earlier findings had already suggested this "triple-G" drug could deliver weight loss rivaling bariatric surgery , and the head-to-head numbers now give Lilly concrete marketing ammunition. Lilly held a 60.1% share of the U.S. obesity and diabetes drug market in the first quarter , and retatrutide is designed to widen that gap.

  • Side Effects Are the Fine Print Investors Shouldn't Ignore. On the top dose, 7.9% of patients quit due to adverse events versus just 2.7% on Ozempic.

Diarrhea hit up to 32.7% of retatrutide patients versus 26.4% on Ozempic. Regulators and insurers will weigh these tolerability gaps when deciding how broadly to approve and cover the drug.

  • A Q3 Earnings Blowout Adds Fuel to the Rally. Lilly's Q3 revenue hit $24.4 billion, up 38.6% year-over-year, beating Wall Street's $22.6 billion estimate, and full-year revenue guidance was lifted to $91.5 billion at the midpoint — 3.3% above analyst consensus.

Mounjaro and Zepbound alone combined for over $16 billion in Q3 revenue. This torrent of cash funds the manufacturing and regulatory push for retatrutide.

  • The Clock Is Now on FDA Filing and Market Sizing. Lilly plans to submit retatrutide for FDA approval in Q1 2027 , after needing extra time to gather manufacturing data.

The global obesity drug market is projected to reach $150 billion by 2035 , and retatrutide targets a specific high-need subset — patients with severe, treatment-resistant obesity — positioning it to expand the total market rather than just cannibalize Lilly's existing drugs. Execution on manufacturing and the regulatory timeline are now the key variables separating a strong pipeline story from actual revenue.